SiBionics and PharmaSens showcase a joint vision for automated insulin delivery at EASD 2026, signaling advancing collaboration in diabetes tech

Executive summary: SiBionics presented its “See More, Act Earlier” initiative at the EASD 2026 congress, describing how continuous glucose monitoring can be tied to upcoming automated insulin delivery approaches, and indicated collaboration with PharmaSens. The initiative points to a tighter integration of sensing and actuation in diabetes care, which could accelerate the development of closed‑loop insulin systems, affect market dynamics for CGM and insulin‑pump makers, and draw regulatory attention.

Who is involved: SiBionics, PharmaSens, attendees and organizers of the EASD 2026 conference.

Likely next: Further joint technical work, potential feasibility trials, and possible formal partnership or product development announcements in the coming months.

At the European Association for the Study of Diabetes congress in Milan, SiBionics presented its “See More, Act Earlier” concept, which links continuous glucose sensing with future insulin delivery strategies, noting collaboration with PharmaSens. The presentation highlights a step toward closed‑loop insulin systems that could improve patient outcomes and stimulate investment in integrated diabetes technologies. No financial terms or timelines were disclosed, but the joint appearance underscores growing cooperation between sensor and drug‑delivery firms in the sector.

What's next — scenarios

Base: feasibility trial launched (50%)

SiBionics and PharmaSens initiate a pilot study of an integrated CGM‑insulin algorithm in Q1 2027.

Positive feedback from EASD attendees
Availability of research funding
Agreement on study protocol

Upside: formal partnership and prototype (30%)

The companies sign a co‑development agreement, delivering a commercial prototype ready for regulatory submission by 2028.

Signing of a memorandum of understanding within three months
Securing venture‑capital or strategic investment
Achievement of predefined technical milestones

Downside: limited follow‑up (20%)

No further joint announcements emerge; each firm pursues separate insulin‑delivery projects.

Absence of measurable outcomes reported after the conference
No subsequent press releases or conference updates
Shift of internal priorities to other programs

What to watch

SiBionics press release outlining trial timelines for integrated insulin delivery (expected within 30 days of 2026‑10‑05).
PharmaSens announcement of sensor accuracy milestones for its next‑gen CGM (expected by end Q4 2026).
Publication of EASD 2026 post‑conference proceedings containing the SiBionics‑PharmaSens abstract (expected December 2026).
FDA pre‑submission meeting request for a closed‑loop insulin system (if filed, likely Q1 2027).
Quarterly earnings calls of major diabetes device firms (e.g., Dexcom, Medtronic) where partnership updates may be discussed (October‑December 2026).

Timeline

2026-10-05 — SIBIONICS et PharmaSens explorent de nouvelles perspectives pour l'administration automatisée d'insuline lors du congrès de l'EASD 2026 (PR Newswire)
2026-10-04 — SIBIONICS и PharmaSens исследуют новые горизонты для автоматической доставки инсулина на EASD 2026 (PR Newswire)
2026-10-04 — SIBIONICS a PharmaSens skúmajú na EASD 2026 nové možnosti automatizovaného podávania inzulínu (PR Newswire)
2026-10-04 — SIBIONICS a PharmaSens zkoumají na konferenci EASD 2026 nové obzory v oblasti automatizovaného podávání inzulínu (PR Newswire)
2026-10-04 — SIBIONICS ve PharmaSens, EASD 2026'da Otomatik İnsülin Uygulamasında Yeni Ufukları Keşfediyor (PR Newswire)
2026-10-04 — SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026 (PR Newswire)

Analysis — what this means

Sectors affected

Continuous glucose monitoring (CGM) device manufacturers
Insulin pump producers
Digital health diabetes care platforms

Regulatory implications

Regulators may require additional clinical evidence for integrated CGM‑insulin algorithms before market approval.
Existing medical device frameworks (FDA, EMA) are likely to apply, with possible updates for interoperability standards.

Historical parallels

Dexcom and InPen announced an integrated CGM‑insulin dosing collaboration in 2023.
Medtronic launched the MiniMed 670G hybrid closed‑loop system in 2016.